Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 11Phase 3 9Phase 1/2 5Phase 4 2Phase 2/3 1

Status

Active not recruiting 8Terminated 1

Sponsor Class

INDUSTRY 9

Study Type

Interventional 9

Sponsor

Cancer Type

Breast 7Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 7Neoplasm Metastasis 3Urogenital Neoplasms 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Phase 3 × Has results × abemaciclib × Clear all
NCT03155997 2026-04-24

monarchE

Eli Lilly and Company

Phase 3 Active not recruiting
5,637 enrolled 12 charts 2 FDA
Breast

Breast Neoplasms

NCT02152631 2026-02-06

JUNIPER

Eli Lilly and Company

Phase 3 Active not recruiting
453 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02763566 2026-02-05

MONARCH plus

Eli Lilly and Company

Phase 3 Active not recruiting
463 enrolled 20 charts
Breast

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Eli Lilly and Company

Phase 3 Active not recruiting
493 enrolled 23 charts
Breast

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

Eli Lilly and Company

Phase 3 Active not recruiting
368 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

Eli Lilly and Company

Phase 3 Active not recruiting
669 enrolled 22 charts
Breast

Breast Neoplasms

NCT04752332 2025-07-15

eMonarcHER

Eli Lilly and Company

Phase 3 Terminated
111 enrolled 9 charts
Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡